1. Home
  2. NEOG vs ADPT Comparison

NEOG vs ADPT Comparison

Compare NEOG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neogen Corporation

NEOG

Neogen Corporation

HOLD

Current Price

$9.31

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$12.68

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOG
ADPT
Founded
1981
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.3B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
NEOG
ADPT
Price
$9.31
$12.68
Analyst Decision
Buy
Strong Buy
Analyst Count
4
9
Target Price
$10.67
$17.78
AVG Volume (30 Days)
2.4M
2.2M
Earning Date
04-09-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
0.02
N/A
Revenue
$894,661,000.00
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
$1.67
$22.72
P/E Ratio
$111.78
N/A
Revenue Growth
N/A
54.77
52 Week Low
$4.32
$6.77
52 Week High
$11.43
$20.76

Technical Indicators

Market Signals
Indicator
NEOG
ADPT
Relative Strength Index (RSI) 47.30 40.74
Support Level $8.93 $12.19
Resistance Level $10.30 $12.92
Average True Range (ATR) 0.53 0.91
MACD 0.13 0.06
Stochastic Oscillator 38.58 19.62

Price Performance

Historical Comparison
NEOG
ADPT

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: